Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health Inc (HIMS) delivers innovative telehealth solutions through its direct-to-consumer platform, connecting users with licensed professionals for personalized care, wellness products, and prescription services. This news hub provides investors and industry observers with essential updates about the company’s operational milestones and market developments.
Access real-time announcements including quarterly earnings reports, strategic partnerships, product expansions, and regulatory filings. Our curated collection ensures you stay informed about HIMS’ position in the competitive digital healthcare sector without needing to track multiple sources.
Key updates across these areas:
Financial Performance: Earnings calls and SEC filings
Service Innovations: New telehealth offerings and treatment categories
Strategic Growth: Partnerships and market expansion initiatives
Regulatory Compliance: FDA updates and healthcare policy impacts
Bookmark this page for streamlined access to verified HIMS developments. Combine these updates with our analysis tools on Stock Titan to monitor the company’s evolving role in reshaping accessible healthcare solutions.
Hims & Hers Health, Inc. reported strong financial results for Q1 2024 with revenue of $278.2 million, up 46% YoY, net income of $11.1 million, and adjusted EBITDA of $32.3 million. Subscribers grew to 1.7 million, a 41% increase YoY. The company raised its full-year 2024 guidance to $1.20 billion to $1.23 billion in revenue and $120 million to $135 million in adjusted EBITDA.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
